Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.

Date publication

octobre 2024

Journal

Blood

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric

Tous les auteurs :
Arrieta-Bolaños E, van der Burg LLJ, Gedde-Dahl T, Robin M, Salmenniemi U, Kröger N, Yakoub-Agha I, Huynh A, Crawley C, Deconinck E, Bulabois CE, Forcade E, Tholouli E, van der Hem JGK, van Balen P, Hoogenboom JD, de Wreede LC, Malard F, Ruggeri A, Fleischhauer K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39102621

Résumé

HLA-DP permissive mismatches can be assigned a direction according to their immunopeptidome divergence across core and noncore subsets. Noncore permissive graft-versus-host mismatches show significantly reduced risks of relapse without increased nonrelapse mortality compared with allele-matched pairs.

Mots clés

Humans, Myelodysplastic Syndromes, therapy, Hematopoietic Stem Cell Transplantation, HLA-DP Antigens, genetics, Male, Graft vs Host Disease, immunology, Histocompatibility Testing, methods, Female, Middle Aged, Adult, Leukemia, immunology, Acute Disease, Aged

Référence

Blood. 2024 10 17;144(16):1747-1751